CapsoVision, Inc. Form 8-K Summary
Business Context and Reporting Period
CapsoVision, Inc. (Nasdaq: CV), a Delaware corporation, filed this Current Report on August 13, 2026. The filing primarily addresses the entry into a material definitive agreement and references the announcement of financial results for the fiscal quarter ended June 30, 2026.
Key Financial Metrics
This Form 8-K does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. The filing references a press release (Exhibit 99.1) containing the results of operations for the quarter ended June 30, 2026, but the text of the press release is not included in the provided source material. Consequently, no financial metrics can be extracted from this document.
Material Changes and Agreements
On August 13, 2026, the Company entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. Key terms include:
- Offering Size: The Company may offer and sell shares of common stock with an aggregate offering price of up to $100,000,000.
- Method: Sales will be conducted via an "at-the-market" offering program on The Nasdaq Capital Market or other trading markets.
- Discretion: The Company retains sole discretion over the number of shares, timing, and price parameters. The Company is not obligated to sell any shares.
- Compensation: Cantor Fitzgerald will receive a cash commission of up to 3.0% of the gross sales proceeds.
- Termination: The agreement terminates upon the sale of all shares or earlier termination by either party.
Guidance, Outlook, and Risks
The filing does not provide specific management commentary, forward-looking guidance, or a detailed risk assessment beyond the standard terms of the sales agreement. The Company intends to file a Registration Statement on Form S-3 to facilitate the offering. The agreement includes customary indemnification and contribution rights for the sales agent.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) to obtain specific financial results for the quarter ended June 30, 2026.
- Monitor future filings for the Registration Statement on Form S-3 and the prospectus supplement.
- Track the Company's stock price and volume to assess the potential dilution impact of the $100 million at-the-market offering.
- Verify the Company's current cash position and liquidity needs to understand the urgency of the capital raise.